Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTES900000.0000000FOR900000.000000FORWave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES900000.0000000ONE YEAR900000.000000FORUroGen Pharma Ltd.M96088105IL001140714008/26/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTES4543895.0000000FOR4543895.000000FORUroGen Pharma Ltd.M96088105IL001140714008/26/2025To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES4543895.0000000ONE YEAR4543895.000000FORReplimune Group, Inc.76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTES2065010.0000000FOR2065010.000000FORAkero Therapeutics, Inc.00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTES5873305.0000000FOR5873305.000000FORArrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTES585682.0000000FOR585682.000000FORIntuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES208000.0000000FOR208000.000000FORBerkshire Hathaway Inc.084670702US084670702605/02/2026Non-binding resolution to approve the compensation of the Company's Named Executive Officers, as described in the 2026 Proxy Statement.SECTION 14A SAY-ON-PAY VOTES50.0000000FOR50.000000FORBerkshire Hathaway Inc.084670702US084670702605/02/2026Non-binding resolution to determine the frequency (whether annual, biennial or triennial) with which shareholders of the Company shall be entitled to have an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTES50.0000000THREE YEARS50.000000FORInsmed Incorporated457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES4842880.0000000FOR4842880.000000FORCelcuity Inc.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES3065298.0000000FOR3065298.000000FORFulgent Genetics, Inc.359664109US359664109805/14/2026To approve, on an advisory basis, compensation awarded to the Company's named executive officers (Say-on-Pay).SECTION 14A SAY-ON-PAY VOTES1289000.0000000FOR1289000.000000FORRepligen Corporation759916109US759916109505/14/2026Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTES1206000.0000000FOR1206000.000000FORUltragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES3648795.0000000FOR3648795.000000FORLarimar Therapeutics, Inc.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1500000.0000000FOR1500000.000000FORLarimar Therapeutics, Inc.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Preferred Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1500000.0000000ONE YEAR1500000.000000FORAlkermes plcG01767105IE00B56GVS1505/20/2026To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1672356.0000000FOR1672356.000000FORRocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026A non-binding, advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES16734217.0000000FOR16734217.000000FORDianthus Therapeutics, Inc.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTES248063.0000000FOR248063.000000FORVerastem, Inc.92337C203US92337C203505/21/2026To approve an advisory vote on the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTES6576306.0000000FOR6576306.000000FOREstablishment Labs Holdings Inc.G31249108VGG31249108405/22/2026To approve, on an advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES2042232.0000000FOR2042232.000000FORCompass Pathways Plc20451W101US20451W101805/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2025SECTION 14A SAY-ON-PAY VOTES9420405.0000000FOR9420405.000000FORCytokinetics, Incorporated23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES696571.0000000FOR696571.000000FORImmunocore Holdings Plc45258D105US45258D105405/27/2026To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES4869798.0000000FOR4869798.000000FORiRhythm Holdings, Inc.450056106US450056106705/27/2026To approve, on a non-binding advisory basis, the named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES1668500.0000000FOR1668500.000000FORNeurocrine Biosciences, Inc.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTES1062072.0000000FOR1062072.000000FORSpyre Therapeutics, Inc.00773J202US00773J202405/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES4191364.0000000FOR4191364.000000FORCastle Biosciences, Inc.14843C105US14843C105305/28/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES2758335.0000000FOR2758335.000000FORAcadia Pharmaceuticals Inc.004225108US004225108405/29/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES7144524.0000000FOR7144524.000000FORTaysha Gene Therapies, Inc.877619106US877619106106/01/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES11636054.0000000FOR11636054.000000FORTaysha Gene Therapies, Inc.877619106US877619106106/01/2026To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES11636054.0000000ONE YEAR11636054.000000FORWaystar Holding Corp.946784105US946784105506/01/2026Indicate, on a non-binding advisory basis, the frequency of future advisory votes to approve the compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1630000.0000000ONE YEAR1630000.000000FORKodiak Sciences Inc.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1487934.0000000FOR1487934.000000FOROruka Therapeutics, Inc.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2052606.0000000FOR2052606.000000FORPTC Therapeutics, Inc.69366J200US69366J200606/02/2026Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.SECTION 14A SAY-ON-PAY VOTES7746415.0000000FOR7746415.000000FORRadNet, Inc.750491102US750491102206/02/2026An advisory vote to approve the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES4294300.0000000FOR4294300.000000FORBeam Therapeutics Inc.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES570394.0000000FOR570394.000000FORNeurogene Inc.64135M105US64135M105306/03/2026To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1362456.0000000FOR1362456.000000FORNeurogene Inc.64135M105US64135M105306/03/2026To hold a non-binding advisory vote on whether future non-binding advisory votes on the compensation paid by the company to its named executive officers should be held every one, two or three years.SECTION 14A SAY-ON-PAY VOTES1362456.0000000ONE YEAR1362456.000000FORStoke Therapeutics, Inc.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES5623525.0000000FOR5623525.000000FORCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES250000.0000000FOR250000.000000FORCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ONA NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES250000.0000000ONE YEAR250000.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES7010964.0000000FOR7010964.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES7010964.0000000ONE YEAR7010964.000000FORSavara Inc.805111101US805111101606/04/2026To approve, on an advisory basis, the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTES5952380.0000000FOR5952380.000000FORTango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES13300620.0000000FOR13300620.000000FORApogee Therapeutics, Inc.03770N101US03770N101906/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES2782097.0000000FOR2782097.000000FORCogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES4560901.0000000FOR4560901.000000FORAquestive Therapeutics, Inc.03843E104US03843E104706/10/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES7426471.0000000FOR7426471.000000FORCompass Therapeutics, Inc.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES4186599.0000000FOR4186599.000000FORCompass Therapeutics, Inc.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES4186599.0000000ONE YEAR4186599.000000FORMilestone Pharmaceuticals Inc.59935V107CA59935V107606/10/2026Say-on-Pay - A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES4331001.0000000FOR4331001.000000FORuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES2586356.0000000FOR2586356.000000FORuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES2586356.0000000ONE YEAR2586356.000000FORMedline Inc.58507V107US58507V107006/11/2026Advisory Vote to Approve Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTES70000.0000000FOR70000.000000FORMedline Inc.58507V107US58507V107006/11/2026Advisory Vote on the Frequency of Votes on Our Executive Compensation.SECTION 14A SAY-ON-PAY VOTES70000.0000000ONE YEAR70000.000000FOROcugen, Inc.67577C105US67577C105306/11/2026Approval, on an advisory basis, of the compensation of Ocugen, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTES50.0000000FOR50.000000FOROcugen, Inc.67577C105US67577C105306/11/2026Approval, on a non-binding advisory basis, of the compensation of Ocugen, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTES50.0000000ONE YEAR50.000000FORCullinan Therapeutics, Inc.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES1705960.0000000FOR1705960.000000FORXencor, Inc.98401F105US98401F105706/16/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers, as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTES6777461.0000000FOR6777461.000000FOR4D Molecular Therapeutics, Inc.35104E100US35104E100106/17/2026Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").SECTION 14A SAY-ON-PAY VOTES146592.0000000FOR146592.000000FORGuardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES449174.0000000FOR449174.000000FORGuardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES449174.0000000ONE YEAR449174.000000FORMadrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTES1993687.0000000FOR1993687.000000FORProtagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES5059053.0000000FOR5059053.000000FORZai Lab Limited98887Q104US98887Q104006/17/2026THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.SECTION 14A SAY-ON-PAY VOTES6574032.0000000FOR6574032.000000FORAllogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES666790.0000000FOR666790.000000FORAllogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES666790.0000000ONE YEAR666790.000000FORCrinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTES1447896.0000000FOR1447896.000000FORDisc Medicine, Inc.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES30000.0000000FOR30000.000000FORUroGen Pharma Ltd.M96088105IL001140714006/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTES4543895.0000000FOR4543895.000000FORAxogen, Inc.05463X106US05463X106306/23/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.SECTION 14A SAY-ON-PAY VOTES653655.0000000FOR653655.000000FOROrchestra Biomed Holdings, Inc.68572M106US68572M106206/23/2026Adoption of an advisory (non-binding) resolution approving the compensation of our "named executive officers".SECTION 14A SAY-ON-PAY VOTES1099900.0000000FOR1099900.000000FOROrchestra Biomed Holdings, Inc.68572M106US68572M106206/23/2026Advisory (non-binding) vote on the frequency of future advisory (non-binding) votes on the compensation of our "named executive officers".SECTION 14A SAY-ON-PAY VOTES1099900.0000000ONE YEAR1099900.000000FORKymera Therapeutics, Inc.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTES240000.0000000FOR240000.000000FORTarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES3346025.0000000FOR3346025.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Mark Pruzanski, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTES1248092.0000000FOR1248092.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Frederic Cren, CEO until September 30, 2025SECTION 14A SAY-ON-PAY VOTES1248092.0000000FOR1248092.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Andrew Obenshain, CEO from October 1, 2025SECTION 14A SAY-ON-PAY VOTES1248092.0000000FOR1248092.000000FORInventiva SA46124U107US46124U107906/30/2026Approve Compensation of Pierre Broqua, Vice-CEO until June 30, 2025SECTION 14A SAY-ON-PAY VOTES1248092.0000000FOR1248092.000000FOR